Timothy R. Smith
St. John's University
40 Papers
273 Citations
Timothy R. Smith is an academic researcher from St. John's University. The author has contributed to research in topics: Migraine & Medicine. The author has an hindex of 18, co-authored 33 publications.
Chat about Author
Papers
Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine
David W. Dodick,Richard B. Lipton,Vincent T. Martin,Vasilios Papademetriou,Wayne D. Rosamond,Antoinette MaassenVanDenBrink,Hassan Loutfi,K. Michael A. Welch,Peter J. Goadsby,Steven R. Hahn,Susan Hutchinson,David B. Matchar,Stephen D. Silberstein,Timothy R. Smith,R. Allan Purdy,Jane Saiers +15 more
TL;DR: The evidence on triptan‐associated cardiovascular risk is evaluated and consensus recommendations for making informed decisions for their use in patients with migraine are formulated.
319
LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.
Christine N. Sang,NM Ramadan,NM Ramadan,NM Ramadan,RG Wallihan,Amy S. Chappell,Frederick G. Freitag,Timothy R. Smith,Stephen D. Silberstein,Kirk W. Johnson,Lee A. Phebus,David Bleakman,Paul L. Ornstein,Brian M. Arnold,Stewart J. Tepper,F Vandenhende +15 more
TL;DR: The efficacy and safety results of LY293558 in this small migraine proof of concept trial, together with supportive preclinical data, provide evidence for a potential role of nonvasoactive AMPA/KA antagonists in treating migraine.
181
Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine
Timothy R. Smith,Abraham Sunshine,Stuart R. Stark,Diane E. Littlefield,Susan E. Spruill,W. James Alexander +5 more
TL;DR: To evaluate the efficacy and tolerability of treatment with a combination of sumatriptan 50 mg (encapsulated) and naproxen sodium 500 mg administered concurrently in the acute treatment of migraine.
171
Cardiovascular Tolerability and Safety of Triptans: A Review of Clinical Data
TL;DR: Triptans are not widely used in clinical practice despite their well‐established efficacy, endorsement by the US Headache Consortium, and the demonstrated need to employ effective intervention to reduce migraine‐associated disability.
127
Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study.
TL;DR: Background.—Approximately 60% of female migraineurs report experiencing migraine in association with menstruation, while 7% to 25% experience attacks almost exclusively with menstruations.
87